Emergent BioSolutions Lands $52.7M U.S. Government Contract for Smallpox and Mpox Vaccine — Emergent BioSolutions Inc.

Event summary

Emergent BioSolutions secured a $52.7 million contract modification from the U.S. government for ACAM2000® vaccine supplies.
Deliveries under the contract are expected to begin in June 2026.
The contract is part of Emergent’s existing 10-year agreement with ASPR (contract number: 75A50119C00071).
Recent regulatory approvals for ACAM2000® in Saudi Arabia and Singapore expand its use against smallpox and mpox.

The big picture

This contract modification underscores the U.S. government’s ongoing commitment to biodefense preparedness, particularly against smallpox and mpox threats. Emergent BioSolutions continues to solidify its role as a key supplier of medical countermeasures, leveraging both domestic contracts and expanding international regulatory approvals to strengthen its market position.

What we're watching

Government Spending: How sustained U.S. government investment in biodefense will impact Emergent’s revenue trajectory.
Regulatory Expansion: Whether international approvals for ACAM2000® will drive additional contract opportunities abroad.
Competitive Dynamics: The pace at which competitors develop alternative smallpox and mpox vaccines, potentially disrupting Emergent’s market position.